Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Celldex Therapeutics develops antibody-based medicines for severe inflammatory, allergic, and autoimmune diseases.
Celldex Therapeutics is a small biotech company that designs antibody drugs aimed at diseases where the body's immune system turns against itself or overreacts — things like chronic hives, food allergies, and other severe inflammatory conditions. It doesn't sell any approved medicines yet. Its business, for now, is running clinical trials and convincing regulators and investors that its drug candidates are safe and actually work.
The company's lead program is a drug called barzolvolimab. It targets a receptor on certain immune cells called mast cells, which are the cells that release histamine and drive allergic and inflammatory reactions — the same basic machinery behind a mosquito bite swelling up, but stuck in the "on" position. By blocking that receptor, the drug is designed to quiet those cells down. Celldex is testing it in chronic spontaneous urticaria (persistent hives), chronic inducible urticaria, and food allergy, among other conditions. The company's earlier history included work in cancer immunotherapies, but it has since focused its pipeline on inflammatory and allergic disease. Celldex earns no product revenue. It funds itself through cash on hand, occasional stock sales, and partnership or licensing deals, and it burns money every quarter on research and trials. That makes it a classic clinical-stage biotech: the entire investment case rests on whether barzolvolimab succeeds in trials and eventually reaches the market. For patients with conditions like chronic hives who don't respond well to existing antihistamines, a new mechanism like this could matter a lot.
The risks are real and obvious. Trials can fail, regulators can say no, and larger competitors with approved allergy and immunology drugs could move into the same space. Celldex's headquarters in the New Haven, Connecticut area puts it in the middle of a dense biotech corridor, which helps with talent and partnerships but doesn't change the fundamental bet: this is a company whose value lives in its data readouts, not in today's sales.
Saved answer · last researched 15 Nov 2026